Document is current

Any future updates will be listed below

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Crossref DOI link: https://doi.org/10.1186/s12933-014-0148-1

Published Online: 2014-10-26

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark